Combining surufatinib with gemcitabine and nab-paclitaxel for pancreatic cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II, multi-centered, open-label study investigates the efficacy and safety of surufatinib combined with gemcitabine and nab-paclitaxel as a peri-operative treatment for patients with locally advanced or borderline resectable pancreatic cancer. Participants will receive surufatinib orally once daily, while gemcitabine and nab-paclitaxel will be administered intravenously on specified days of a 28-day cycle. The study also aims to explore potential therapeutic biomarkers to better understand treatment responses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically or cytologically confirmed high-risk resectable or borderline resectable pancreatic cancer;
* 18-75 years old (including 18 and 75 years old);
* No BRCA1/2 or PALB2 mutation;
* No previous systematic treatment or radiotherapy;
* Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;
* Life expectancy ≥ 6 months;
* At least one measurable lesion according to RECIST version 1.1;
* Adequate organ and bone marrow functions: -Absolute neutrophil count≥1.5x10\^9/L; -Platelet count≥100x10\^9/L; -Hemoglobin≥9g/dL; -Serum bilirubin≤1.5x the upper limit of normal (ULN); -Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5x ULN; -Serum creatinine≤1.5x ULN or endogenous creatinine clearance rate ≥ 60ml / min; -INR≤1.5×ULN, PT and APTT≤1.5×ULN；
* Women of childbearing age need to take effective contraceptive measures.

Exclusion Criteria:

* With distant metastasis;
* Have received blood transfusion treatment, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF) within 14 days before enrollment;
* Have received any surgery or invasive treatment or operation within 4 weeks before enrollment (except venous catheterization, puncture and drainage, etc.);
* Allergic to the study drug or any of its adjuvants;
* researchers judged clinically significant electrolyte abnormalities;
* History of serious cardiovascular and cerebrovascular diseases: -Cerebrovascular accident (excluding lacunar cerebral infarction, minor cerebral ischemia or transient ischemic attack), myocardial infarction, unstable angina pectoris, and poorly controlled arrhythmia (including QTc interval ≥ 450ms for male and ≥ 470ms for female) occurred within 6 months before the first administration of the study drug (QTc interval was calculated by fridericia formula); -New York Heart Association (NYHA) cardiac function classification \> grade II or left ventricular ejection fraction (LVEF) \< 50%;
* With active ulcer, intestinal perforation and intestinal obstruction;
* Uncontrollable malignant ascites (defined as ascites that cannot be controlled by diuretics or puncture according to the judgment of the investigator);
* Clinically significant electrolyte abnormalities judged by researchers;
* With active bleeding or obvious evidence of bleeding tendency;
* Hypertension that cannot be controlled by drugs: systolic blood pressure ≥ 150 mmHg and / or diastolic blood pressure ≥ 100 mmHg;
* Women who are pregnant or lactating;
* Urinary protein ≥ ++, or the 24-hour urine protein quantification is greater than 1.0g;
* Concurrent tumors within 5 years (except treated cervical carcinoma in situ, basal cell carcinoma);
* Any disease or state that affects the absorption of drugs, or the subject cannot take oral drugs;
* Known human immunodeficiency virus (HIV) infection;
* History of clinically significant hepatic disease, including, but not limited to, known hepatitis B virus (HBV) infection with HBV DNA positive (copies ≥1×10\^4/ml or \>2000 IU/ml); known hepatitis C virus infection with HCV RNA positive (copies ≥1×10\^3/m); hepatitis and cirrhosis;
* Have any other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other conditions that makes the subject not suitable for enrolling according to the judgment of the investigator.

Where it's running

• Tianjin Medical University Cancer Institute and Hospital
  Tianjin, Tianjin, China Recruiting

Study contacts

• Principal investigator: Jihui Hao, M.D. — Tianjin Medical University Cancer Institute and Hospital
• Study coordinator: Jihui Hao, M.D.
• Email: ec_tjcih@126.com
• Phone: 022-23524155

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining surufatinib and camrelizumab with chemotherapy for advanced pancreatic cancer

  This study is testing a new combination of treatments for people with advanced pancreatic cancer to see if it works better than the standard options.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing · NCT05218889

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer

  This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895498

• Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer

  This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.

  Recruiting Ningbo Medical Center Lihuili Hospital · Ningbo, Zhejiang · NCT07892573

• Blood protein biomarkers to help diagnose pancreatic cancer in adults

  This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.

  Recruiting Grigore T. Popa University of Medicine and Pharmacy · Iași · NCT07875582

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.